Adjuvant Drugs are Placed under Strict Control again and the Market Pattern of Oncology Drugs may Change

发布日期:2016-07-01访问次数: 信息来源:http://www.pharmadl.com字号:[ ]


One of the largest drug markets in China is facing regulation now, which may bring about changes in the existing drug market.

On March 22, 2016, the National Health and Family Planning Commission issued the Notice on Strengthening Standard Tumor Diagnosis and Treatment. According to the data from sample hospitals in 22 cities around the country, the oncology drug and immunomodulator market has expanded from RMB 4.87 billion in 2005 to RMB 24.84 billion in 2014. Due to the increasing cancer incidence, oncology drugs and immunomodulators rank first in terms of purchase value in the sample hospitals.

An analysis report from McKinsey also pointed that the oncology drug market as a whole appears to have a trend of strong growth, which will continue in the future, as aging population, lifestyle changes and environmental pollution lead to increased cancer incidence. Along with the enhancement of disease awareness, the progress of diagnostic techniques and the improved access to the diagnosis and treatment services, an increasing number of cancer patients seek medical treatment. In addition, the improved affordability of patients is another important reason behind the expansion of the oncology drug market.

The highlights of the Notice are as follows:

1. Standards shall be worked out for cancer treatment. The National Health and Family Planning Commission and the State Administration of Traditional Chinese Medicine will continue to organize the deliberation, formulation and revision of the diagnosis and treatment standards and clinical pathways for common cancers and will deliver guidance for implementation in various areas. Medical institutions must strictly implement the cancer-related diagnosis and treatment standards and clinical pathways and provide standard diagnosis and treatment services.

2. Adjuvant drugs shall be placed under strict control, and oncology drugs shall be subject to restrictions on the number of product types and specifications. Medical institutions must strictly control the number of oncology drugs and adjuvant drugs used within the respective institutions. For the drug types with the same generic name, the number of drug specifications shall be restricted. Priority shall be given to the use of the drugs that are included in the National Essential Drugs List, the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List and the New Rural Cooperative Medical System Drug List, and the drugs subject to national negotiation. The classified use principles and use ratio should be defined for oncology drugs and adjuvant drugs, and the use ratio of adjuvant drugs should be reduced continuously.

Hence adjuvant drugs are placed under strict control again and the rules on the restricted use of adjuvant drugs are further detailed. And the priority oncology drugs will benefit thereby. This is particularly the case with the drugs subject to national negotiation, which get one more weight in price negotiations due to the priority.

 





打印本页 关闭窗口
 
Produced By 大汉网络 大汉版通发布系统